AHA shares proposals to lower Medicare drug prices with Congress
In a statement submitted to the Senate Finance Committee for a hearing yesterday on lowering drug prices in Medicare, AHA encouraged Congress to implement policies that would increase generic alternatives and discourage anti-competitive tactics while maintaining incentives to develop innovative new therapies. AHA also called for policies to increase transparency in drug pricing; provide rebates to Medicare when a drug’s average manufacturer or sales price exceeds inflation; better align incentives in the Part D reinsurance program; and protect the 340B Drug Pricing Program.
Related News Articles
Headline
The House Energy and Commerce Committee held a markup April 29 where it advanced the AHA-supported SUPPORT Act (H.R. 2483). The legislation would reauthorize…
Perspective
Just 16 days from now, more than 1,000 hospital and health system leaders from across the country will arrive in Washington, D.C., for the 2025 AHA Annual…
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription…
Headline
The Department of Commerce yesterday released notices announcing national security investigations on imports of pharmaceuticals, pharmaceutical ingredients and…
Chairperson's File
This is an incredibly dynamic and transformative time for health care. One resource I have found incredibly helpful in speaking with many of you and engaging…
Perspective
Congressional lawmakers are heading home for a two-week district work period after both the Senate and House passed a revised budget resolution for fiscal year…